- Home
- OZ vs INBX Comparison
OZ vs INBX Comparison
Compare OZ & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- INBX
- Stock Information
- Founded
- OZ 2020
- INBX 2010
- Country
- OZ United States
- INBX United States
- Employees
- OZ N/A
- INBX N/A
- Industry
- OZ
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- INBX Health Care
- Exchange
- OZ Nasdaq
- INBX Nasdaq
- Market Cap
- OZ 254.2M
- INBX 237.5M
- IPO Year
- OZ N/A
- INBX 2020
- Fundamental
- Price
- OZ $65.55
- INBX $15.27
- Analyst Decision
- OZ
- INBX Hold
- Analyst Count
- OZ 0
- INBX 1
- Target Price
- OZ N/A
- INBX N/A
- AVG Volume (30 Days)
- OZ 6.3K
- INBX 118.3K
- Earning Date
- OZ 01-01-0001
- INBX 08-13-2024
- Dividend Yield
- OZ N/A
- INBX N/A
- EPS Growth
- OZ N/A
- INBX N/A
- EPS
- OZ N/A
- INBX 118.83
- Revenue
- OZ $1,700,000.00
- INBX $1,687,000.00
- Revenue This Year
- OZ N/A
- INBX N/A
- Revenue Next Year
- OZ N/A
- INBX N/A
- P/E Ratio
- OZ N/A
- INBX $0.12
- Revenue Growth
- OZ N/A
- INBX 24.26
- 52 Week Low
- OZ $42.75
- INBX $10.80
- 52 Week High
- OZ $83.00
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- OZ 39.96
- INBX 50.01
- Support Level
- OZ $69.01
- INBX $14.67
- Resistance Level
- OZ $70.76
- INBX $15.91
- Average True Range (ATR)
- OZ 0.77
- INBX 0.65
- MACD
- OZ -0.50
- INBX -0.21
- Stochastic Oscillator
- OZ 8.15
- INBX 20.48
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.